Johnson & Johnson (NYSE:JNJ)
Despite beating Wall Street’s fourth quarter earnings and revenue expectations, Johnson & Johnson lost investor confidence on a projected 2018 operational revenue growth of 3.5% to 4.5%. J&J’s $30B acquisition of Actelion last summer contributed 4.2% towards their Worldwide Pharmaceutical sales growth of 8.4% to $36.3B in the quarter.
From Jeff Auxier (Trades, Portfolio)'s first-quarter 2018 shareholder letter.
